Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer

High-grade serous ovarian cancer (HGSOC) is the predominant and most lethal histological type of epithelial ovarian cancer. During the last few years, several new treatment options with PARP inhibitors have emerged. The FDA has approved the PARP inhibitor olaparib (Lynparza™) as maintenance treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Irem Durmaz, Jönsson, Jenny-Maria, Hedenfalk, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916751/
https://www.ncbi.nlm.nih.gov/pubmed/31857852
http://dx.doi.org/10.18632/oncotarget.27363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916751/
https://www.ncbi.nlm.nih.gov/pubmed/31857852
http://dx.doi.org/10.18632/oncotarget.27363

Ejemplares similares